85 related articles for article (PubMed ID: 11881103)
1. Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future.
Weber M
J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2 Suppl 2():S12-6. PubMed ID: 11881103
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber MA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
5. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications.
Unger T
J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2 Suppl 2():S4-7. PubMed ID: 11881101
[TBL] [Abstract][Full Text] [Related]
8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the efficacy of ARBs across the cardiovascular continuum.
Gupta M; Honos GN; Velazquez EJ; Chung N; Oigman W; Maggioni AP
Curr Med Res Opin; 2010 May; 26(5):1203-18. PubMed ID: 20302552
[TBL] [Abstract][Full Text] [Related]
10. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
Nickenig G; Ostergren J; Struijker-Boudier H
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
[TBL] [Abstract][Full Text] [Related]
11. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
12. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?
Volpe M; Ruilope LM; McInnes GT; Waeber B; Weber MA
J Hum Hypertens; 2005 May; 19(5):331-9. PubMed ID: 15744333
[TBL] [Abstract][Full Text] [Related]
14. New treatment guidelines for a patient with diabetes and hypertension.
Mogensen CE
J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
[TBL] [Abstract][Full Text] [Related]
15. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
17. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension.
Motwani JG
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):72-8. PubMed ID: 12228846
[TBL] [Abstract][Full Text] [Related]
18. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
Weber MA
Rev Cardiovasc Med; 2002; 3(4):183-91. PubMed ID: 12556752
[TBL] [Abstract][Full Text] [Related]
19. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
